Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] 10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS

ATLAS is an international trial of the main effects of prolonging adjuvant tamoxifen. It involves 15 000 women with early breast cancer, randomised in 1995–2005 at 402 centres in many countries. Its 2013 findings1 showed that in oestrogen receptor (ER)-positive disease, 5 years of tamoxifen is significantly less effective than 10 years in reducing 15-year breast cancer mortality, and its 20-year findings are to be reported in 2018.

email